Identifying cancer therapies that induce remission is a major challenge for drug discovery and therapy guidance. PreComb has developed the 3DTwin® technology to create a clinical drug testing network to do just that. The network is being explored in two ways: first, to provide pharmaceutical companies with a unified global platform to test drugs directly on patient tumors for ex vivo clinical trials, and second, to use the results to create a scalable database of patient-specific drug responses. By bridging the gap between the pharmaceutical industry and the patient, we believe that we can create significant synergies between the two stakeholders to support the pharmaceutical and therapeutic decision making process. We seek investors and pharmaceutical partners who share our passion for developing technologies that streamline cancer drug discovery, increasing therapeutic value for cancer patients.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
